Perioperative Enfortumab Vedotin Plus Pembrolizumab Improves EFS, OS and pCR in Patients with MIBC Who Are Ineligible for Cisplatin By Ogkologos - February 23, 2026 158 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the KEYNOTE-905/EV-303 study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Strengthens Global Oncology Collaboration Through its Growing Presence in the Asia-Pacific Pemigatinib Prolongs mPFS Over Chemotherapy in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements FDA Approves Atezolizumab for Adjuvant Treatment of Muscle Invasive Bladder Cancer in Patients with Molecular Residual Disease MOST POPULAR FDA Approves Brexucabtagene Autoleucel for Relapsed or Refractory B-Cell Precursor Acute... October 7, 2021 EMA Adopts a Positive Opinion for Biosimilar Denosumab May 28, 2025 Cabozantinib Plus Nivolumab and Ipilimumab Results in Longer PFS in Previously... May 19, 2023 Cancer vaccines – where are we? February 24, 2023 Load more HOT NEWS Sing Anyway Common Questions About COVID-19 and Cancer: Answers for Patients and Survivors Ivonescimab Plus Chemotherapy Significantly Improves PFS in Patients with NSCLC Previously... High Sensitivity of Mismatch Repair–Deficient Locally Advanced Rectal Cancer to Single-Agent...
